On Friday June 8, 2018, the CSO of Pantarhei Carole Verhoeven lectured on the treatment of breast cancer with the fetal estrogen estetrol in a scientific symposium entitled ‘Estrogens and breast cancer’. The other lecture (A lesson in contracts. What can we learn from the discrepant breast cancer findings in the WHI?) was presented by Bob Langer. The symposium was chaired by Wulf Utian.

For more information, please read the abstract: Abstract IMS Treatment of breast cancer with the fetal estrogen estetrol.

On March 8, 2018 Pantarhei Bioscience participated in a scientific symposium entitled Estetrol and Breast Cancer. The lectures were presented by Richard J. Santen (Estetrol in animal in vivo studies), Risto Erkkola (Estetrol in ex vivo explant cultures of human breast cancer tissue) and Herjan Coelingh Bennink (Estetrol treatment of advanced breast cancer). The symposium was chaired by Ludwig Kiesel and Herjan Coelingh Bennink.

The first patient has been enrolled in the Phase I/II clinical trial assessing safety and efficacy of estetrol (E4) in postmenopausal women with advanced ER+ breast cancer. The study is a multi-center, open-label, dose-escalation study with a 3 + 3 cohort design to determine the recommended dose of E4 for the treatment of patients with advanced breast cancer. In total 9-18 patients will be enrolled at three centers in Germany.

The main objectives of this study are to evaluate the safety, the effects on estrogen deficiency symptoms and the preliminary anti-tumor activity of E4 in patients with advanced breast cancer.

On Wednesday May 24, 2017 Pantarhei sponsored a symposium entitled “Estrogens for breast- and prostate cancer treatment”. Lectures were presented by Herjan Coelingh Bennink (High dose estrogens for breast cancer), Carole Verhoeven (Estetrol for breast cancer) and Yvette Zimmerman (Estetrol for prostate cancer). The session was chaired by Ludwig Kiesel and Cobi Reisman.

The CEO of Pantarhei, Herjan Coelingh Bennink, will be presenting at the BioCapital Europe Conference on March 15, 2017 in Amsterdam. An ideal opportunity to meet us and discuss possibilities to collaborate, partner with or invest in Pantarhei’s programmes.